SPC25 and prostate adenocarcinoma: In addition, SPC25 has been identified to be significantly upregulated and is associated with poor survival in LIHC18, prostate adenocarcinoma (PRAD)19, BC20, LUAD, and lung squamous cell adenocarcinoma (LUSC)21.